Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain
As a non-antibody scaffold, monobodies based on the fibronectin type III (FN3) domain overcome antibody size and complexity while maintaining analogous binding loops. However, antibodies and their derivatives remain the gold standard for the design of new therapeutics. In response, clinical-stage th...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI AG
2020-03-01
|
| Sarja: | Cells |
| Aiheet: | |
| Linkit: | https://www.mdpi.com/2073-4409/9/3/610 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|